What is the treatment for erythema nodosum?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Erythema Nodosum

The first-line treatment for erythema nodosum is to identify and treat the underlying cause, while managing symptoms with NSAIDs such as acetylsalicylic acid, ibuprofen, naproxen, or indomethacin for 2-12 weeks based on clinical resolution. 1

Diagnostic Evaluation

Before initiating treatment, a thorough diagnostic workup is essential to identify potential underlying causes:

  • Complete blood count with differential
  • Erythrocyte sedimentation rate and/or C-reactive protein
  • Testing for streptococcal infection (throat culture, rapid antigen test)
  • Chest radiograph
  • Additional testing based on clinical suspicion of specific causes 1, 2

Treatment Algorithm

1. Treat the Underlying Cause

Erythema nodosum is often associated with:

  • Streptococcal infections (most common cause in children)
  • Sarcoidosis (common in adults)
  • Inflammatory bowel disease
  • Tuberculosis
  • Medications (including oral contraceptives)
  • Other systemic diseases 1, 3, 2

2. Symptomatic Treatment

First-Line Therapy:

  • NSAIDs for pain and inflammation management
    • Options: acetylsalicylic acid, ibuprofen, naproxen, indomethacin
    • Duration: 2-12 weeks based on clinical resolution 1, 3

For Recurrent or Resistant Cases:

  • Colchicine is recommended as first-line treatment for recurrent cases, particularly when associated with Behçet's disease or inflammatory bowel disease 1

For Severe Cases Unresponsive to First-Line Therapy:

  • Systemic corticosteroids may be considered
    • Use brief courses to minimize side effects
    • Not generally recommended for routine use due to the self-limited nature of the disease 1

For Resistant Cases or Frequent Relapses:

  • Immunomodulators such as azathioprine or TNF-α antagonists (infliximab, adalimumab) may be considered 1

3. Supportive Care Measures

  • Rest and elevation of affected limbs
  • Compression stockings to reduce edema
  • Avoidance of prolonged standing or sitting
  • Adequate pain management 1

Special Considerations

Pregnancy

Pregnancy can create an optimal background for erythema nodosum to develop. Treatment options must be carefully selected, and consultation with an obstetrician is essential before prescribing medications 4.

Contraindications and Cautions

  • NSAIDs may be contraindicated in patients with peptic ulcer disease or renal impairment
  • Systemic steroids should be avoided when an underlying infection hasn't been ruled out 1

Monitoring and Follow-up

  • Regular assessment of treatment response
  • Monitoring for recurrence after treatment discontinuation
  • Evaluation for signs of underlying disease progression 1

Common Pitfalls to Avoid

  1. Misdiagnosis: Erythema nodosum is commonly confused with cellulitis, infected insect bites, or minor trauma, especially in emergency settings 1

  2. Failure to identify underlying causes: Always investigate for systemic diseases, as erythema nodosum may be the first sign of conditions like tuberculosis, sarcoidosis, or inflammatory bowel disease 2

  3. Overuse of corticosteroids: While effective, systemic steroids should be reserved for severe cases unresponsive to first-line therapy due to potential side effects 1, 3

  4. Inadequate treatment duration: Relapse may occur after discontinuation, requiring reinstitution of therapy for another 4-8 weeks 1

References

Guideline

Erythema Nodosum Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Erythema nodosum: a sign of systemic disease.

American family physician, 2007

Research

Erythema nodosum.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.